Plain-English translation of NCT06430736 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
CAR-T cell therapy is a powerful treatment for certain blood cancers like lymphoma, leukemia, and myeloma. However, it can cause serious side effects called cytokine release syndrome and neurologic complications. This trial is testing whether giving tocilizumab — a medication that blocks inflammation — before CAR-T treatment starts can prevent these side effects, compared to giving it only when side effects appear.
Up to 90% of CAR-T patients experience inflammation-related side effects that can be severe and dangerous. Doctors want to know if giving this medication ahead of time prevents these complications altogether, rather than waiting to treat them after they happen.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups: one group receives the medication one hour before their CAR-T infusion, and the other group only receives it if side effects develop. Both groups will be monitored closely during and after their CAR-T treatment, likely with hospital stays and regular check-ups over the first three months. Your doctors will track whether you develop side effects, how long you stay in the hospital, and whether you need blood transfusions.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Switzerland